secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kodiak Sciences Inc. (KOD)
CIK:        0001468748
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0000950170-22-008988
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kodiak Sciences Q1 net loss $95.7M ($1.83/share); updates KSI-301 program after Ph2b/3 miss
--------------------------------------------------------------------------------

- Net loss $95.7M ($1.83/share) vs $50.4M ($0.98/share) in Q1 2021.
- R&D expenses $76.2M, up 89% YoY; G&A $19.6M, up 92% YoY; cash $671.7M.
- KSI-301 Phase 2b/3 wet AMD missed primary endpoint; ongoing Phase 3 studies modified to reduce undertreatment risk.
- BEACON top-line data expected August 2022; DAYLIGHT, GLEAM, GLIMMER data mid-2023.
- Commercial manufacturing facility in Visp, Switzerland reached mechanical completion March 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1468748/000095017022008988/0000950170-22-008988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1468748/000095017022008988/kod-20220510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-008988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer